FDA has pegged the development of blood pathogen detection technology a “critical priority” to reduce the cost of blood screenings, improve safety of the blood supply and increase the donor pool, outgoing FDA Commissioner Scott Gottlieb and biologics center director Peter Marks say in a Tuesday (March 26) statement. The FDA officials underscore the need to develop better technologies that can help detect and reduce contamination of blood products, and they say FDA is working with “a variety of different...